Cipla and Qilu Pharmaceutical secure US biosimilar rights for Keytruda

The Indian drugmaker partnered with a Chinese rival to license and distribute a pembrolizumab biosimilar, expanding its footprint in the lucrative oncology market.

3 Sept, 16:23 — 3 Sept, 16:23

Post Share

Sources

Showing 1 of 1 sources

morningstar4h ago

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US - Morningstar

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US Morningstar

Read full article →

Cipla and Qilu Pharmaceutical secure US biosimilar rights for Keytruda

Sources

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US - Morningstar

Related Stories

Lululemon Faces Deepening Sales Decline and Lowers Annual Revenue Forecast Again

Volkswagen Approves Major Restructuring Plan With 50,000 Job Cuts

Air Canada Expands Network With New Transatlantic and European Routes

Crusoe Secures $13 Billion AI Cloud Computing Deal With Jane Street